Printer Friendly

CROP GENETICS AUGMENTS BIOPESTICIDE PRODUCTION; STREAMLINES RESEARCH OPERATIONS

 COLUMBIA, Md., Sept. 16 /PRNewswire/ -- Crop Genetics (NASDAQ: CROP) today announced a reallocation and reduction of its staff to reflect the changing nature of the company's operations. CGI's Chairman and CEO, Joe Kelly, said that as its first products reach the marketplace it has become necessary to focus more of its resources on manufacturing and reduce the size of the research organization. Effective Oct. 1, approximately 25 percent of the company's workforce will be involved in the production of biopesticides based upon environmentally friendly insect viruses. Until now, CGI had devoted substantially all of its resources to research. Kelly said the adjustment and realignment of personnel follows the recent EPA approval of CGI's first InStar(TM) virus insecticide and the completion of the company's manufacturing facility.
 Mr. Kelly also said the transition to a more production oriented organization would eliminate 20 positions and reduce annual expenses by approximately $2 million. "Our number one priority is to make the company profitable," said Mr. Kelly. "Allocating more of our resources to the production of InStar biopesticides is the clearest route to making the company self-sufficient. Scaling back our research costs reduces our break-even point and allows us to be profitable more quickly."
 InStar virus product sales are expected next year through the company's alliance with DuPont. Mr. Kelly reaffirmed the company was in sound financial condition with more than $12 million in cash and no debt.
 Kelly said that the increased focus on InStar production will not affect the strategy for commercialization of the company's two other technologies, X-tend(TM) and InCide(R).
 "Summer field trials of our X-tend bioherbicide showed weed control comparable to the major synthetic chemical herbicides." X-tend is a biological approach to weed control which, if commercialized, should reduce the amount of chemical herbicides applied for total vegetation control. Mr. Kelly stated that with recently filed patents and positive field trials, CGI is in a position to commence discussions with a corporate partner to develop the X-tend technology.
 Zeneca PLC (formerly part of Imperial Chemical Industries PLC) and CGI are jointly assessing the commercial potential of the company's InCide Technology. Mr. Kelly said the InCide Mid-West field trials are nearing completion and the yield results should be available in late October.
 CGI is engaged in the discovery, basic development and manufacture of environmentally safe crop protection products.
 -0- 9/16/93
 /CONTACT: Joe Kelly, chief executive officer of Crop Genetics International, 410-381-3800, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, Inc., 212-696-4455/
 (CROP)


CO: Crop Genetics International ST: Maryland IN: AGR ENV SU: PDT PER

WB-OS -- NY040 -- 2652 09/16/93 11:40 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1993
Words:438
Previous Article:UNITED WATER RESOURCES AND GWC CORPORATION ANNOUNCE MERGER AGREEMENT; MERGED COMPANY WILL BE SECOND LARGEST IN U.S. WATER UTILITY INDUSTRY
Next Article:SCHULLER INTERNATIONAL ANNOUNCES ACQUISITION OF COMMERCIAL/INDUSTRIAL ROOFING BUSINESS FROM OWENS-CORNING FIBERGLAS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters